Abpro Corporation
Biotechnology company developing next generation antibody therapeutics.
Based in MA
AI Overview
With $150K in lobbying spend across 12 quarterly filings, Abpro Corporation is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2021 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $90K |
| 2022 | $60K |
| 2023 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Abpro Corporation disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Disaster Planning, Health Issues
Advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics.
Issues related to advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics - no specific legislation.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.